These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Muijsers RB; Curran MP; Perry CM Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112 [TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131 [TBL] [Abstract][Full Text] [Related]
7. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Bakris G; Sica D; Ram V; Fagan T; Vaitkus PT; Anders RJ Am J Hypertens; 2002 Jan; 15(1 Pt 1):53-7. PubMed ID: 11824861 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Schiavi P; Jochemsen R; Guez D Fundam Clin Pharmacol; 2000; 14(2):139-46. PubMed ID: 10796061 [TBL] [Abstract][Full Text] [Related]
9. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Zachariah PK; Sheps SG; Schirger A; Spiekerman RE; O'Brien PC; Simpson KK Am J Cardiol; 1986 Feb; 57(7):74D-79D. PubMed ID: 3953429 [TBL] [Abstract][Full Text] [Related]
10. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Shimada K; Ogihara T; Saruta T; Kuramoto K; Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495 [TBL] [Abstract][Full Text] [Related]
11. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group. McMahon FG; Reder RF J Clin Pharmacol; 1989 Nov; 29(11):1003-7. PubMed ID: 2689469 [TBL] [Abstract][Full Text] [Related]
12. Influence of food on the bioavailability of a sustained-release verapamil preparation. Conway EL; Phillips PA; Drummer OH; Louis WJ J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632 [TBL] [Abstract][Full Text] [Related]
13. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study]. Vulpis V; Seccia TM; Ricci S; Pirrelli A Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676 [TBL] [Abstract][Full Text] [Related]
14. Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients. Cardillo C; Musumeci V; Savi L; Guardigli R; Mores N; Folli G Eur J Clin Pharmacol; 1988; 34(6):549-53. PubMed ID: 3169108 [TBL] [Abstract][Full Text] [Related]
15. Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension. Gradman AH; Frishman WH; Kaihlanen PM; Wong SC; Friday KJ Am J Cardiol; 1992 Dec; 70(20):1571-5. PubMed ID: 1466325 [TBL] [Abstract][Full Text] [Related]
16. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy. Denardo SJ; Gong Y; Cooper-DeHoff RM; Farsang C; Keltai M; Szirmai L; Messerli FH; Bavry AA; Handberg EM; Mancia G; Pepine CJ PLoS One; 2015; 10(4):e0122726. PubMed ID: 25835002 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Hla KK; Henry JA; Latham AN Br J Clin Pharmacol; 1987 Nov; 24(5):661-4. PubMed ID: 3435694 [TBL] [Abstract][Full Text] [Related]
18. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Karim A; Piergies A Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Schaefer HG; Heinig R; Ahr G; Adelmann H; Tetzloff W; Kuhlmann J Eur J Clin Pharmacol; 1997; 51(6):473-80. PubMed ID: 9112062 [TBL] [Abstract][Full Text] [Related]
20. The effects of age on the pharmacodynamics and pharmacokinetics of two formulations of verapamil. Hosie J; Hosie G; Meredith PA J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S60-2. PubMed ID: 2475690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]